Ido Sagi – PhD Student @HUJI, 2017 Kaye Innovation Award winner for leading research that yielded the first successful isolation and maintenance of haploid embryonic stem cells in humans.
Reporter: Aviva Lev-Ari, PhD, RN
Ido Sagi – PhD Student, Silberman Institute of Life Sciences, HUJI, Israel
- Ido Sagi’s research focuses on studying genetic and epigenetic phenomena in human pluripotent stem cells, and his work has been published in leading scientific journals, including Nature, Nature Genetics and Cell Stem Cell.
- Ido Sagi received BSc summa cum laude in Life Sciences from the Hebrew University, and currently pursues a PhD at the laboratory of Prof. Nissim Benvenisty at the university’s Department of Genetics in the Alexander Silberman Institute of Life Sciences.
- 2017 Kaye Innovation Award winner for leading research that yielded the first successful isolation and maintenance of haploid embryonic stem cells in humans.
The Kaye Innovation Awards at the Hebrew University of Jerusalem have been awarded annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of the Hebrew University to develop innovative methods and inventions with good commercial potential, which will benefit the university and society.
- Hebrew University of Jerusalem’s Azrieli Center for Stem Cells and Genetic Research, led research that yielded the first successful isolation and maintenance of haploid embryonic stem cells in humans.
- Together with Prof. Nissim Benvenisty, Director of the Azrieli Center, Sagi showed that this new human stem cell type will play an important role in human genetic and medical research. It will aid our understanding of human development – for example, why we reproduce sexually instead of from a single parent. It will make genetic screening easier and more precise, by allowing the examination of single sets of chromosomes. And it is already enabling the study of resistance to chemotherapy drugs, with implications for cancer therapy.
Read more at https://www.breakingisraelnews.com/90561/hebrew-u-isolates-haploid-human-stem-cells-changing-future-of-medicine/#impRGtg0syOSFGtZ.99- He is a fellow of the Adams Fellowship of the Israel Academy of Sciences and Humanities, and
- Has recently received the Rappaport Prize for Excellence in Biomedical Research.
- Enterpreneur – Based on this research, Yissum, the Technology Transfer arm of the Hebrew University, launched the company NewStem, which is developing a diagnostic kit for predicting resistance to chemotherapy treatments. By amassing a broad library of human pluripotent stem cells with different mutations and genetic makeups, NewStem plans to develop diagnostic kits for personalized medication and future therapeutic and reproductive products.
Read more at https://www.breakingisraelnews.com/90561/hebrew-u-isolates-haploid-human-stem-cells-changing-future-of-medicine/#impRGtg0syOSFGtZ.99
Publications – Ido Sagi
Haploidy in Humans: An Evolutionary and Developmental Perspective.
- Authors:
- Ido Sagi,
- Nissim Benvenisty
June 2017
Identification and propagation of haploid human pluripotent stem cells.
- Authors:
- Ido Sagi,
- Dieter Egli,
- Nissim Benvenisty
November 2016
Haploid Human Embryonic Stem Cells: Half the Genome, Double the Value.
- Authors:
- Atilgan Yilmaz,
- Mordecai Peretz,
- Ido Sagi,
- Nissim Benvenisty
November 2016
Derivation and differentiation of haploid human embryonic stem cells.
- Authors:
- Ido Sagi,
- Gloryn Chia,
- Tamar Golan-Lev,
- Mordecai Peretz,
- Uri Weissbein,
- Lina Sui,
- Mark V Sauer,
- Ofra Yanuka,
- Dieter Egli,
- Nissim Benvenisty
April 2016
Pluripotent stem cells in disease modelling and drug discovery.
- Authors:
- Yishai Avior,
- Ido Sagi,
- Nissim Benvenisty
March 2016
Comparable frequencies of coding mutations and loss of imprinting in human pluripotent cells derived by nuclear transfer and defined factors.
- Authors:
- Bjarki Johannesson,
- Ido Sagi,
- Athurva Gore,
- Daniel Paull,
- Mitsutoshi Yamada,
- Tamar Golan-Lev,
- Zhe Li,
- Charles LeDuc,
- Yufeng Shen,
- Samantha Stern,
- Nanfang Xu,
- Hong Ma,
- Eunju Kang,
- Shoukhrat Mitalipov,
- Mark V Sauer,
- Kun Zhang,
- Nissim Benvenisty,
- Dieter Egli
November 2014
Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells.
- Authors:
- Mitsutoshi Yamada,
- Bjarki Johannesson,
- Ido Sagi,
- Lisa Cole Burnett,
- Daniel H Kort,
- Robert W Prosser,
- Daniel Paull,
- Michael W Nestor,
- Matthew Freeby,
- Ellen Greenberg,
- Robin S Goland,
- Rudolph L Leibel,
- Susan L Solomon,
- Nissim Benvenisty,
- Mark V Sauer,
- Dieter Egli
June 2014
The noncoding RNA IPW regulates the imprinted DLK1-DIO3 locus in an induced pluripotent stem cell model of Prader-Willi syndrome.
- Authors:
- Yonatan Stelzer,
- Ido Sagi,
- Ofra Yanuka,
- Rachel Eiges,
- Nissim Benvenisty
June 2014
Involvement of parental imprinting in the antisense regulation of onco-miR-372-373.
- Authors:
- Yonatan Stelzer,
- Ido Sagi,
- Nissim Benvenisty
November 2013
Stem cells: Aspiring to naivety.
- Authors:
- Ido Sagi,
- Nissim Benvenisty
Other related articles on Genetic and Epigenetic phenomena in human pluripotent stem cells published by LPBI Group can be found in the following e-Books on Amazon.com
e-Books in Medicine
9 results for Kindle Store : “Aviva Lev-Ari”
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.